Related Experiment Video

Updated: Jun 4, 2026

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
13:18

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

Molecular cross-regulation between PPAR-γ and other signaling pathways: implications for lung cancer therapy

Ajaya Kumar Reka1, Moloy T Goswami, Rashmi Krishnapuram

  • 1Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA. ajayar@umich.edu

Lung Cancer (Amsterdam, Netherlands)
|March 1, 2011
PubMed

Insights

Peroxisome proliferator-activated receptor gamma (PPAR-γ) ligands, used for diabetes, show promise in cancer therapy. This review explores how PPAR-γ activation impacts tumor growth and its cross-regulation with other pathways for lung cancer treatment.

Area of Science:

  • Molecular Biology
  • Oncology
  • Endocrinology

Background:

  • Peroxisome proliferator-activated receptor gamma (PPAR-γ) is a nuclear receptor involved in adipocyte differentiation and lipid metabolism.
  • PPAR-γ ligands are clinically used for type II diabetes with a favorable safety profile.
  • PPAR-γ activation influences cancer hallmarks by affecting tumor microenvironment cells.

Purpose of the Study:

  • To review the molecular mechanisms by which PPAR-γ ligands affect cancer progression.
  • To discuss the cross-regulation of PPAR-γ with other signaling pathways.
  • To highlight the therapeutic potential of PPAR-γ in lung cancer.

Main Methods:

  • Literature review of preclinical studies on PPAR-γ and cancer.
  • Analysis of signaling pathways modulated by PPAR-γ activation.
  • Focus on PPAR-γ cross-talk with other molecular targets.

Main Results:

  • Preclinical studies demonstrate PPAR-γ ligand efficacy in controlling tumor proliferation, apoptosis, angiogenesis, inflammation, and metastasis.
  • PPAR-γ activation impacts multiple cell types within the tumor microenvironment.
  • Various signaling pathways are implicated in PPAR-γ's anti-cancer effects.

Conclusions:

  • PPAR-γ activation exhibits pleiotropic effects beneficial for cancer therapy.
  • Understanding PPAR-γ cross-regulation with signaling pathways is crucial for developing novel lung cancer treatments.
  • PPAR-γ represents a promising therapeutic target for various cancers, particularly lung cancer.

More Related Videos

Primary Sjogren's Syndrome Associated with Lung Adenocarcinoma: Probing the Potential Common Pathogenic Mechanisms and Experimental Verification10:21

Primary Sjogren's Syndrome Associated with Lung Adenocarcinoma: Probing the Potential Common Pathogenic Mechanisms and Experimental Verification

Published on: September 20, 2024

Related Concept Videos

Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...